Bevacizumab dose adjustment for colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adjusting the dose of bevacizumab based on your blood levels can improve first-line treatment for metastatic colorectal cancer that can't be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have metastatic colorectal cancer that cannot be fully removed by surgery.
- You have not had treatment for metastatic cancer before (or if you had chemotherapy after surgery, it ended more than 6 months ago for a single drug, or more than 12 months ago for a combination).
- Your overall health allows you to be up and about (ECOG score 0-2).
- Your blood tests show adequate kidney, liver, and blood cell counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study compares two treatment plans for people with metastatic colorectal cancer that got worse or caused side effects after first chemotherapy. It looks at whether adding bevacizumab (a medicine that targets blood vessels feeding tumors) improves outcomes versus using a different chemotherapy approach.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
This trial tests a new schedule of two drugs—bevacizumab and trifluridine/tipiracil—given every two weeks instead of more often. The goal is to reduce severe low white blood cell counts (neutropenia) while still treating advanced colorectal cancer that has not responded to several previous treatments.
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
Hear when a new Unresectable Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.